
iBio IBIO
$ 1.19
1.24%
iBio Long Term Debt Current | IBIO
Annual Long Term Debt Current iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 546 K | 490 K | 436 K | 389 K | 91 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 546 K | 91 K | 390 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
194 M | $ 263.04 | 0.49 % | $ 465 B | ||
|
AbCellera Biologics
ABCL
|
5.82 M | $ 11.41 | 2.15 % | $ 3.41 B | ||
|
Aclaris Therapeutics
ACRS
|
551 K | $ 5.53 | 6.02 % | $ 678 M | ||
|
ADC Therapeutics SA
ADCT
|
538 K | $ 1.09 | 3.74 % | $ 139 M | ||
|
Amryt Pharma plc
AMYT
|
1.54 M | - | - | $ 621 M | ||
|
Evelo Biosciences
EVLO
|
2.26 M | - | -14.46 % | $ 27.9 M | ||
|
Allakos
ALLK
|
4.16 M | - | - | $ 28.6 M | ||
|
Chimerix
CMRX
|
719 K | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
1.16 M | - | - | $ 401 M | ||
|
ADMA Biologics
ADMA
|
1.1 M | $ 8.61 | 0.16 % | $ 2.05 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
84 K | - | -9.21 % | $ 2.55 M | ||
|
89bio
ETNB
|
727 K | - | - | $ 1.55 B | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.66 M | - | - | $ 384 M | ||
|
Fusion Pharmaceuticals
FUSN
|
4.16 M | - | - | $ 1.41 B | ||
|
Guardion Health Sciences
GHSI
|
3.81 K | - | -0.31 % | $ 3.64 M | ||
|
Genocea Biosciences
GNCA
|
2.35 M | - | -15.0 % | $ 3.04 M | ||
|
Gritstone Oncology
GRTS
|
6.9 M | - | 0.42 % | $ 213 M | ||
|
G1 Therapeutics
GTHX
|
1.28 M | - | - | $ 370 M | ||
|
Harpoon Therapeutics
HARP
|
2.42 M | - | - | $ 763 M | ||
|
HOOKIPA Pharma
HOOK
|
552 K | - | -6.92 % | $ 79.4 M | ||
|
Intercept Pharmaceuticals
ICPT
|
3.04 M | - | - | $ 643 M | ||
|
IGM Biosciences
IGMS
|
7.12 M | - | - | $ 76.9 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
Intra-Cellular Therapies
ITCI
|
4.23 M | - | - | $ 13.6 B | ||
|
Kinnate Biopharma
KNTE
|
892 K | - | - | $ 123 M | ||
|
Chinook Therapeutics
KDNY
|
4.95 M | - | - | $ 2.6 B | ||
|
Kaleido Biosciences
KLDO
|
16.1 M | - | -3.69 % | $ 12.4 M | ||
|
Kronos Bio
KRON
|
3.39 M | - | 1.49 % | $ 50.8 M | ||
|
Karuna Therapeutics
KRTX
|
2.84 M | - | - | $ 12.2 B | ||
|
La Jolla Pharmaceutical Company
LJPC
|
154 K | - | - | $ 154 M | ||
|
LogicBio Therapeutics
LOGC
|
1.23 M | - | - | $ 229 M | ||
|
Lumos Pharma
LUMO
|
282 K | - | - | $ 35.3 M | ||
|
Merrimack Pharmaceuticals
MACK
|
13.3 M | - | - | $ 216 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
9 M | - | - | $ 23.9 M | ||
|
Mirati Therapeutics
MRTX
|
7.84 M | - | - | $ 3.3 B | ||
|
NexImmune
NEXI
|
68.8 K | - | 70.13 % | $ 4.12 M | ||
|
9 Meters Biopharma
NMTR
|
61.7 K | - | -42.97 % | $ 1.05 M | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
396 K | - | -37.48 % | $ 476 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
23 K | - | -19.68 % | $ 18.4 M | ||
|
ObsEva SA
OBSV
|
696 K | - | -15.52 % | $ 10.5 M | ||
|
Oncorus
ONCR
|
1.13 M | - | -8.54 % | $ 3.19 M | ||
|
OncoSec Medical Incorporated
ONCS
|
1.11 M | - | 31.87 % | $ 1.61 M | ||
|
Oncternal Therapeutics
ONCT
|
173 K | - | -24.12 % | $ 1.56 M | ||
|
Opiant Pharmaceuticals
OPNT
|
338 K | - | - | $ 109 M | ||
|
Orchard Therapeutics plc
ORTX
|
6.42 M | - | 1.02 % | $ 90.8 M |